Journal of thrombosis and haemostasis : JTH · 2026
Development and validation of a risk assessment model for hospital-acquired venous thrombosis in medical in-patients with cancer.
СтатьяВалидационное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Martin Karlyn A, Wilkinson Katherine, Sparks Andrew, Roetker Nicholas S, Gergi Mansour, Herrera Diego Adrianzen, Schaefer Jordan K, Li Ang, Gangaraju Radhika, Sprague Brian L, Holmes Chris, Zakai Neil A
Аннотация
BACKGROUND: Existing risk assessment models (RAM) for hospital-acquired venous thromboembolism (VTE) have not been widely assessed in people with cancer or have underperformed.
OBJECTIVES: We aimed to develop and validate a RAM for hospital-acquired VTE for patients with active cancer admitted to medical services.
METHODS: We included admissions to medical services of adults ≥ 18 years with active cancer at 6 academic health systems from January 1, 2016, to December 31, 2022. We excluded patients with VTE at admission. Four systems formed the development cohort and 2 the validation cohort. First, we refit a prior RAM for medical patients by adding cancer type. Then, we then developed a de-novo RAM using Bayesian least absolute shrinkage and selection operator logistic regression.
RESULTS: Among 65 626 development and 58 124 validation admissions, hospital-acquired VTE occurred in 411 (0.6%) and 298 (0.5%), respectively. After refitting the existing RAM, the area under the receiver operating curve and calibration slope were 0.60 and 0.60, respectively. The de-novo model identified predictors (coefficient): prior VTE (1.08), malnutrition (0.42), hematologic malignancy excluding aggressive lymphomas (0.35), lung cancer (0.33), inflammatory comorbidity (0.41), age [≥75, -0.55; 60-75 years, -0.07]), anticoagulation level at admission (full, 0.45; prophylactic, -0.06), and chronic obstructive pulmonary disease (-0.04). The area under the receiver operating curve and calibration slope were 0.68 and 1.07 in the development cohort and 0.64 and 0.84 in the validation cohort, respectively.
CONCLUSION: The hospital-acquired RAM developed and validated in this study for patients with cancer performed better than a noncancer-specific model. This tool will support individualized risk assessment in medical in-patients with cancer.
OBJECTIVES: We aimed to develop and validate a RAM for hospital-acquired VTE for patients with active cancer admitted to medical services.
METHODS: We included admissions to medical services of adults ≥ 18 years with active cancer at 6 academic health systems from January 1, 2016, to December 31, 2022. We excluded patients with VTE at admission. Four systems formed the development cohort and 2 the validation cohort. First, we refit a prior RAM for medical patients by adding cancer type. Then, we then developed a de-novo RAM using Bayesian least absolute shrinkage and selection operator logistic regression.
RESULTS: Among 65 626 development and 58 124 validation admissions, hospital-acquired VTE occurred in 411 (0.6%) and 298 (0.5%), respectively. After refitting the existing RAM, the area under the receiver operating curve and calibration slope were 0.60 and 0.60, respectively. The de-novo model identified predictors (coefficient): prior VTE (1.08), malnutrition (0.42), hematologic malignancy excluding aggressive lymphomas (0.35), lung cancer (0.33), inflammatory comorbidity (0.41), age [≥75, -0.55; 60-75 years, -0.07]), anticoagulation level at admission (full, 0.45; prophylactic, -0.06), and chronic obstructive pulmonary disease (-0.04). The area under the receiver operating curve and calibration slope were 0.68 and 1.07 in the development cohort and 0.64 and 0.84 in the validation cohort, respectively.
CONCLUSION: The hospital-acquired RAM developed and validated in this study for patients with cancer performed better than a noncancer-specific model. This tool will support individualized risk assessment in medical in-patients with cancer.